Curtis Ruegg

Curtis Ruegg has extensive experience in the biotech and pharmaceutical industry. Curtis is currently the Chief Development Officer/Chief Operating Officer at NaNotics LLC. Prior to this, they served as a Member of the Board of Directors at Paramag Biosciences, Inc. and CEO and Member of the Board of Directors at Paramag Biosciences. Curtis has also held leadership positions at Amphivena Therapeutics Inc., Parvus Therapeutics, Inc., Allergan, Revance Therapeutics, CoTherix, InterMune, and AP Cells, Inc. Their roles in these companies have included President and CEO, Executive Vice President of R&D, SVP of Technical Operations, Vice President of Development, and Vice President of R&D. Ruegg's work experience spans from 1999 to the present.

Curtis Ruegg has a Bachelor of Science (BS) degree in Toxicology from the University of California, Davis. Curtis then pursued a Postdoctoral Fellowship in Immunology at Stanford University School of Medicine. Curtis completed their education with a PhD in Pharmacology from The Johns Hopkins University School of Medicine.